119 related articles for article (PubMed ID: 26942837)
1. New perspectives on targeted therapy in ovarian cancer.
Coward JI; Middleton K; Murphy F
Int J Womens Health; 2015; 7():189-203. PubMed ID: 25678824
[TBL] [Abstract][Full Text] [Related]
2. Application of anti-angiogenic drugs in ovarian cancer from the perspective of bibliometrics.
Song S; Meng S; Yin R
Asian J Surg; 2024 May; 47(5):2228-2229. PubMed ID: 38331619
[No Abstract] [Full Text] [Related]
3. Impact of molecular profiling on overall survival of patients with advanced ovarian cancer.
Herzog TJ; Spetzler D; Xiao N; Burnett K; Maney T; Voss A; Reddy S; Burger R; Krivak T; Powell M; Friedlander M; McGuire W
Oncotarget; 2016 Apr; 7(15):19840-9. PubMed ID: 26942886
[TBL] [Abstract][Full Text] [Related]
4. Ovarian cancer: Novel molecular aspects for clinical assessment.
Palmirotta R; Silvestris E; D'Oronzo S; Cardascia A; Silvestris F
Crit Rev Oncol Hematol; 2017 Sep; 117():12-29. PubMed ID: 28807232
[TBL] [Abstract][Full Text] [Related]
5. Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment.
Papa A; Caruso D; Strudel M; Tomao S; Tomao F
J Transl Med; 2016 Sep; 14():267. PubMed ID: 27634150
[TBL] [Abstract][Full Text] [Related]
6. What Is the Place of PARP Inhibitors in Ovarian Cancer Treatment?
Liu JF; Matulonis UA
Curr Oncol Rep; 2016 May; 18(5):29. PubMed ID: 26984416
[TBL] [Abstract][Full Text] [Related]
7. Targeted Therapies for Ovarian Cancer.
Grunewald T; Ledermann JA
Best Pract Res Clin Obstet Gynaecol; 2017 May; 41():139-152. PubMed ID: 28111228
[TBL] [Abstract][Full Text] [Related]
8. Targeting the hallmarks of ovarian cancer: The big picture.
Petrillo M; Nero C; Amadio G; Gallo D; Fagotti A; Scambia G
Gynecol Oncol; 2016 Jul; 142(1):176-183. PubMed ID: 27058837
[TBL] [Abstract][Full Text] [Related]
9. Weekly dose-dense chemotherapy for ovarian cancer.
Tanday S
Lancet Oncol; 2016 Apr; 17(4):e138. PubMed ID: 26948925
[No Abstract] [Full Text] [Related]
10. Olaparib for the treatment of epithelial ovarian cancer.
McLachlan J; Banerjee S
Expert Opin Pharmacother; 2016; 17(7):995-1003. PubMed ID: 26967466
[TBL] [Abstract][Full Text] [Related]
11. Advances in ovarian cancer therapy.
Cortez AJ; Tudrej P; Kujawa KA; Lisowska KM
Cancer Chemother Pharmacol; 2018 Jan; 81(1):17-38. PubMed ID: 29249039
[TBL] [Abstract][Full Text] [Related]
12. Development of substituted benzimidazoles as inhibitors of human aldehyde dehydrogenase 1A isoenzymes.
Takahashi C; Chtcherbinine M; Huddle BC; Wilson MW; Emmel T; Hohlman RM; McGonigal S; Buckanovich RJ; Larsen SD; Hurley TD
Chem Biol Interact; 2024 Mar; 391():110910. PubMed ID: 38364885
[TBL] [Abstract][Full Text] [Related]
13. FBXO22 Promotes Growth and Metastasis and Inhibits Autophagy in Epithelial Ovarian Cancers
Li M; Zhao X; Yong H; Shang B; Lou W; Wang Y; Bai J
Front Pharmacol; 2021; 12():778698. PubMed ID: 34950036
[TBL] [Abstract][Full Text] [Related]
14. Targeted Therapies in the Management of Ovarian Cancer: A Focus on Older Patients.
Lum C; Steer CB
Drugs Aging; 2017 Nov; 34(11):821-831. PubMed ID: 29086349
[TBL] [Abstract][Full Text] [Related]
15. Anti-tumour activity of tivozanib, a pan-inhibitor of VEGF receptors, in therapy-resistant ovarian carcinoma cells.
Momeny M; Sabourinejad Z; Zarrinrad G; Moghaddaskho F; Eyvani H; Yousefi H; Mirshahvaladi S; Poursani EM; Barghi F; Poursheikhani A; Dardaei L; Bashash D; Ghazi-Khansari M; Tavangar SM; Dehpour AR; Yaghmaie M; Alimoghaddam K; Ghavamzadeh A; Ghaffari SH
Sci Rep; 2017 Apr; 7():45954. PubMed ID: 28383032
[TBL] [Abstract][Full Text] [Related]
16. Targeted agents and combinations in ovarian cancer: where are we now?
McLachlan J; Lima JP; Dumas L; Banerjee S
Expert Rev Anticancer Ther; 2016; 16(4):441-54. PubMed ID: 26942837
[TBL] [Abstract][Full Text] [Related]
17. Clinical Trials of Novel Targeted Therapies in Ovarian Cancer: Moving Beyond Poly ADP Ribose Polymerase (PARP) Inhibitors.
Guo Q; Yang Q; Li J; Liu G; Nikoulin I; Jia S
Curr Pharm Biotechnol; 2018; 19(14):1114-1121. PubMed ID: 30585545
[TBL] [Abstract][Full Text] [Related]
18. Targeted therapy of ovarian cancer including immune check point inhibitor.
Kim JY; Cho CH; Song HS
Korean J Intern Med; 2017 Sep; 32(5):798-804. PubMed ID: 28823141
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
